Company research
MANNKIND CORP
CIK 899460Updated Oct 6, 2026
SecurityMNKD · NASDAQ · equity
Historical securities (1)
MNKDW · OTC · warrant · closed Feb 9, 2016MNKD price & chart
Loading TradingView…
NASDAQ:MNKD on TradingView ↗About the company
MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
In the news
MannKind to Host Conference Call Today to Discuss Afrezza Pediatric Approval ↗
Longevity Biotech Stocks Surge as $27 Trillion Healthcare Shift Favors Cell Restoration News provided by USA News Group Jan 29, 2026, 13:31 ET Share this article Share to X Share this article Share to X Issued on behalf of Avant Technologies Inc. VANCOUVER, BC , Jan. 29, 2026 /PRNewswire/ -- USA Ne ↗
Recent filings
144 filing
Other Events
Items 8.01, 9.01
424B7 filing
SCHEDULE 13G - filed by Rubric Capital Management LP regarding MANNKIND CORP
144 filing
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q2 2024 | Q1 2026 | Q1 2025 | Q1 2024 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||
| AssetsUSD | 494,640,000Source | 464,200,000Source | 732,304,000Source | 411,697,000Source | 443,836,000Source | 744,403,000Source | 410,141,000Source | 480,879,000Source | 792,182,000Source | 393,843,000Source | 475,198,000Source | 295,282,000Source |
| Property, Plant and Equipment, NetUSD | 82,652,000Source | 85,339,000Source | 85,160,000Source | 82,965,000Source | 85,144,000Source | 82,554,000Source | 83,781,000Source | 83,620,000Source | 82,423,000Source | 85,365,000Source | 84,220,000Source | 45,126,000Source |
| GoodwillUSD | 1,931,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 1,931,000Source | 2,428,000Source |
| Intangible Assets, Net (Excluding Goodwill)USD | 5,120,000Source | 5,313,000Source | 4,976,000Source | 5,169,000Source | 1,033,000Source | 5,024,000Source | 5,217,000Source | 1,053,000Source | 5,072,000Source | 5,265,000Source | 1,073,000Source | 1,153,000Source |
| Current assets: | ||||||||||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 127,392,000Source | 62,373,000Source | 52,929,000Source | 57,006,000Source | 96,643,000Source | 52,834,000Source | 47,312,000Source | 193,272,000Source | 74,882,000Source | 46,339,000Source | 238,480,000Source | 69,767,000Source |
| Accounts Receivable, after Allowance for Credit Loss, CurrentUSD | 17,383,000Source | 18,184,000Source | 43,207,000Source | 27,142,000Source | 23,346,000Source | 28,137,000Source | 28,900,000Source | 19,912,000Source | 38,367,000Source | 11,804,000Source | 14,901,000Source | 16,801,000Source |
| Inventory, NetUSD | 26,972,000Source | 26,663,000Source | 44,419,000Source | 28,491,000Source | 24,753,000Source | 49,166,000Source | 28,892,000Source | 26,442,000Source | 35,313,000Source | 27,886,000Source | 28,545,000Source | 21,772,000Source |
| Assets, CurrentUSD | 358,837,000Source | 327,664,000Source | 245,712,000Source | 279,027,000Source | 325,940,000Source | 251,160,000Source | 273,737,000Source | 383,102,000Source | 291,579,000Source | 268,306,000Source | 373,393,000Source | 234,896,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 54,447,000Source | 31,229,000Source | 46,956,000Source | 44,409,000Source | 30,080,000Source | 39,996,000Source | 34,404,000Source | 36,019,000Source | 46,553,000Source | 31,360,000Source | 34,848,000Source | 25,477,000Source |
| Operating Lease, Right-of-Use AssetUSD | 11,294,000Source | 13,637,000Source | 10,847,000Source | 11,788,000Source | 4,073,000Source | 11,291,000Source | 12,565,000Source | 4,392,000Source | 11,822,000Source | 13,109,000Source | 4,685,000Source | 6,714,000Source |
| Other Assets, NoncurrentUSD | 19,131,000Source | 26,422,000Source | 17,123,000Source | 19,624,000Source | 15,658,000Source | 22,015,000Source | 28,055,000Source | 7,447,000Source | 20,129,000Source | 26,757,000Source | 7,426,000Source | 9,718,000Source |
| LIABILITIES AND EQUITY | ||||||||||||
| LiabilitiesUSD | 539,192,000Source | 674,126,000Source | 799,501,000Source | 466,739,000Source | 669,616,000Source | 803,598,000Source | 468,759,000Source | 710,849,000Source | 843,204,000Source | 472,659,000Source | 721,366,000Source | 545,820,000Source |
| Stockholders’ equity: | ||||||||||||
| Common Stock, Value, IssuedUSD | 3,070,000Source | 2,753,000Source | 3,099,000Source | 3,063,000Source | 2,740,000Source | 3,089,000Source | 3,039,000Source | 2,703,000Source | 3,078,000Source | 3,029,000Source | 2,700,000Source | 2,638,000Source |
| Retained Earnings (Accumulated Deficit)USD | -3,180,008,000Source | -3,209,241,000Source | -3,231,607,000Source | -3,187,993,000Source | -3,220,791,000Source | -3,212,575,000Source | -3,188,661,000Source | -3,218,777,000Source | -3,195,956,000Source | -3,201,819,000Source | -3,229,407,000Source | -3,217,469,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 137,000Source | 588,000Source | -19,000Source | 1,257,000Source | — | -4,000Source | 1,174,000Source | — | 115,000Source | 1,109,000Source | — | — |
| Stockholders' Equity Attributable to ParentUSD | -44,552,000Source | -209,926,000Source | -67,197,000Source | -55,042,000Source | -225,780,000Source | -59,195,000Source | -58,618,000Source | -229,970,000Source | -51,022,000Source | -78,816,000Source | -246,168,000Source | -250,538,000Source |
| Additional Paid in Capital, Common StockUSD | 3,132,249,000Source | 2,995,974,000Source | 3,161,330,000Source | 3,128,631,000Source | 2,992,271,000Source | 3,150,295,000Source | 3,125,830,000Source | 2,986,104,000Source | 3,141,741,000Source | 3,118,865,000Source | 2,980,539,000Source | 2,964,293,000Source |
| Liabilities and EquityUSD | 494,640,000Source | 464,200,000Source | 732,304,000Source | 411,697,000Source | 443,836,000Source | 744,403,000Source | 410,141,000Source | 480,879,000Source | 792,182,000Source | 393,843,000Source | 475,198,000Source | 295,282,000Source |
| Current liabilities: | ||||||||||||
| Liabilities, CurrentUSD | 109,130,000Source | 72,101,000Source | 142,898,000Source | 111,826,000Source | 80,012,000Source | 134,561,000Source | 115,937,000Source | 99,896,000Source | 171,031,000Source | 81,837,000Source | 104,125,000Source | 67,296,000Source |
| Operating Lease, Liability, CurrentUSD | 1,957,000Source | 2,431,000Source | 2,076,000Source | 2,067,000Source | 1,773,000Source | 1,957,000Source | 2,373,000Source | 1,611,000Source | 2,110,000Source | 2,423,000Source | 1,423,000Source | 1,304,000Source |
| Accounts Payable, CurrentUSD | 7,269,000Source | 6,444,000Source | 11,042,000Source | 10,257,000Source | 9,556,000Source | 16,144,000Source | 5,041,000Source | 7,149,000Source | 9,034,000Source | 6,792,000Source | 9,580,000Source | 11,052,000Source |
| Operating Lease, Liability, NoncurrentUSD | 10,258,000Source | 12,167,000Source | 9,687,000Source | 10,656,000Source | 3,272,000Source | 10,281,000Source | 11,141,000Source | 3,645,000Source | 10,689,000Source | 11,645,000Source | 3,925,000Source | 5,343,000Source |
| Additional Financial Items | ||||||||||||
| Accrued Liabilities, CurrentUSD | 31,419,000Source | 37,386,000Source | 60,768,000Source | 30,915,000Source | 40,952,000Source | 58,598,000Source | 40,103,000Source | 42,291,000Source | 64,628,000Source | 40,293,000Source | 42,036,000Source | 35,553,000Source |
| Long-term DebtUSD | 109,652,000Source | 227,941,000Source | 319,085,000Source | 36,166,000Source | 227,577,000Source | 318,722,000Source | 36,109,000Source | 264,148,000Source | 354,641,000Source | 36,051,000Source | 268,699,000Source | 273,490,000Source |
| Short-term InvestmentsUSD | 132,643,000Source | 189,215,000Source | 58,201,000Source | 121,979,000Source | 151,118,000Source | 81,027,000Source | 134,229,000Source | 107,457,000Source | 96,464,000Source | 150,917,000Source | 56,619,000Source | 101,079,000Source |
cash flow · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash flows from operating activities: | ||||||||||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | — | — | — | — | — | — | -16,619,000Source | 13,158,000Source | 5,863,000Source | 27,588,000Source | -11,938,000Source | -87,400,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||||||||||
| Depreciation and amortization | — | — | — | — | — | — | —Source | —Source | —Source | —Source | —Source | —Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | — | — | — | — | — | — | 6,455,000Source | 5,385,000Source | 24,195,000Source | 21,358,000Source | 17,649,000Source | 13,447,000Source |
| Changes in operating assets and liabilities: | ||||||||||||
| Increase (Decrease) in Accounts ReceivableUSD | — | — | — | — | — | — | -10,290,000Source | 17,096,000Source | 4,762,000Source | -2,652,000Source | -2,345,000Source | 11,807,000Source |
| Increase (Decrease) in InventoriesUSD | — | — | — | — | — | — | 14,928,000Source | 1,472,000Source | 6,624,000Source | 3,196,000Source | 11,347,000Source | 5,670,000Source |
| Increase (Decrease) in Accounts PayableUSD | — | — | — | — | — | — | 7,110,000Source | -1,751,000Source | -16,711,000Source | -2,788,000Source | -1,473,000Source | 4,096,000Source |
| Deferred Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | -19,467,000Source | 3,874,000Source | 6,812,000Source | -9,940,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | — | — | — | — | — | — | -5,365,000Source | -6,377,000Source | 18,255,000Source | 42,511,000Source | 34,094,000Source | -80,679,000Source |
| Cash flows from investing activities: | ||||||||||||
| Payments to Acquire Businesses, Net of Cash AcquiredUSD | — | — | — | — | — | — | — | — | 347,742,000Source | — | — | 15,341,000Source |
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | — | — | — | — | — | 18,725,000Source | 5,962,000Source | -304,803,000Source | -96,649,000Source | -1,988,000Source | 4,874,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | — | — | — | — | — | — | 1,880,000Source | 330,000Source | 4,566,000Source | 9,693,000Source | 42,441,000Source | 7,589,000Source |
| Cash flows from financing activities: | ||||||||||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | — | — | — | — | — | — | -35,406,000Source | 1,390,000Source | 315,099,000Source | -137,266,000Source | 136,607,000Source | 21,388,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | — | — | — | — | — | — | -22,046,000Source | 975,000Source | 28,551,000Source | -191,404,000Source | 168,713,000Source | -54,417,000Source |
| Supplemental disclosure of cash flow information: | ||||||||||||
| Interest Paid, Excluding Capitalized Interest, Operating ActivitiesUSD | — | — | — | — | — | — | 9,746,000Source | 3,012,000Source | 14,716,000Source | 17,506,000Source | 18,279,000Source | 8,852,000Source |
| Income Taxes Paid, NetUSD | — | — | — | — | — | — | 63,000Source | 207,000Source | 1,705,000Source | 4,262,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Share-based Payment Arrangement, ExpenseUSD | — | — | 4,318,000Source | 5,227,000Source | 10,226,000Source | 7,520,000Source | 6,455,000Source | 5,385,000Source | 24,195,000Source | 21,358,000Source | 17,649,000Source | 13,447,000Source |
| Amortization of Debt Issuance CostsUSD | — | — | 106,000Source | 363,000Source | — | 57,000Source | — | 57,000Source | 646,000Source | 1,352,000Source | 1,454,000Source | — |
| Amortization of Debt Issuance Costs and DiscountsUSD | — | — | — | — | — | — | 452,000Source | 109,000Source | 854,000Source | 1,646,000Source | 2,085,000Source | 1,453,000Source |
| Amortization of Intangible AssetsUSD | — | — | — | — | 4,367,000Source | — | 4,367,000Source | — | 3,973,000Source | — | — | — |
| DepreciationUSD | — | — | 2,012,000Source | 2,099,000Source | 2,031,000Source | 2,039,000Source | 2,015,000Source | 2,058,000Source | 8,100,000Source | 7,300,000Source | 4,500,000Source | 3,300,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 120,000Source | -2,454,000Source | 486,000Source | -5,363,000Source | 1,318,000Source | -2,509,000Source | -7,749,000Source | 3,907,000Source | -1,916,000Source | 4,811,000Source |
| Gain (Loss) on Disposition of AssetsUSD | — | — | — | — | — | — | — | — | — | -565,000Source | — | — |
| Gain (Loss) on Extinguishment of DebtUSD | — | — | — | — | — | — | -917,000Source | — | — | -20,444,000Source | — | — |
| General and Administrative ExpenseUSD | — | — | — | 10,823,000Source | — | — | — | — | — | — | 42,538,000Source | 37,720,000Source |
| GoodwillUSD | — | — | 1,931,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 67,595,000Source | 1,931,000Source | 1,931,000Source | 2,428,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Impairment of Intangible Assets (Excluding Goodwill)USD | — | — | — | — | — | — | — | — | — | — | — | 0Source |
| Income Tax Expense (Benefit)USD | — | — | -204,000Source | 1,320,000Source | -106,000Source | 272,000Source | 253,000Source | 459,000Source | -4,456,000Source | 2,930,000Source | 1,561,000Source | 0Source |
| InterestExpenseNonoperatingUSD | — | — | 1,364,000Source | 1,801,000Source | 11,894,000Source | 285,000Source | 7,478,000Source | 4,645,000Source | 13,830,000Source | 11,981,000Source | — | — |
| Investment Income, InterestUSD | — | — | 2,628,000Source | 3,179,000Source | 1,022,000Source | 1,832,000Source | 1,429,000Source | 1,956,000Source | 8,053,000Source | 12,615,000Source | 6,154,000Source | 2,513,000Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 7,985,000Source | 11,550,000Source | -19,032,000Source | 668,000Source | -16,619,000Source | 13,158,000Source | 5,863,000Source | 27,588,000Source | -11,938,000Source | -87,400,000Source |
| Nonoperating Income (Expense)USD | — | — | -11,115,000Source | 110,000Source | -18,788,000Source | -4,359,000Source | -14,699,000Source | -8,676,000Source | -37,394,000Source | -42,069,000Source | -19,055,000Source | -23,290,000Source |
| Operating ExpensesUSD | — | — | — | 18,023,000Source | 29,540,000Source | 20,568,000Source | — | — | 87,960,000Source | 76,602,000Source | 62,771,000Source | 57,497,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 32,000Source | -4,992,000Source | — | -2,777,000Source | — | -1,009,000Source | 32,000Source | 122,000Source | -102,000Source |
| Payments of Financing CostsUSD | — | — | — | — | — | — | — | — | 7,266,000Source | — | — | — |
| Proceeds from Stock Options ExercisedUSD | — | — | — | — | — | — | — | — | 6,400,000Source | 2,900,000Source | 1,200,000Source | 3,000,000Source |
income statement · annual statements
| Line item | Q4 2025 | Q4 2024 | Q3 2025 | Q3 2024 | Q2 2026 | Q2 2025 | Q1 2026 | Q1 2025 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total RevenueUSD | — | — | 82,130,000Source | 70,079,000Source | 109,374,000Source | 76,527,000Source | 90,171,000Source | 78,354,000Source | 348,966,000Source | 285,504,000Source | 198,962,000Source | 99,770,000Source |
| Cost of RevenueUSD | — | — | 4,498,000Source | 3,197,000Source | 14,409,000Source | 4,607,000Source | 7,509,000Source | 3,768,000Source | 26,800,000Source | 17,429,000Source | 20,863,000Source | 16,003,000Source |
| Gross Profit (Calculated) · Derived | — | — | — | — | — | — | — | — | — | — | — | — |
| Selling, General and Administrative ExpenseUSD | — | — | 29,088,000Source | 23,916,000Source | 58,302,000Source | 31,622,000Source | 54,085,000Source | 25,014,000Source | 144,135,000Source | 94,329,000Source | — | — |
| Operating Income (Loss)USD | — | — | 18,896,000Source | 12,760,000Source | -350,000Source | 5,299,000Source | -1,667,000Source | 22,293,000Source | 38,801,000Source | 72,587,000Source | 8,678,000Source | -64,110,000Source |
| Other Nonoperating Income (Expense)USD | — | — | — | 32,000Source | -4,992,000Source | — | -2,777,000Source | — | -1,009,000Source | 32,000Source | 122,000Source | -102,000Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | — | — | 7,781,000Source | 12,870,000Source | -19,138,000Source | 940,000Source | -16,366,000Source | 13,617,000Source | 1,407,000Source | 30,518,000Source | -10,377,000Source | -87,400,000Source |
| Income Tax Expense (Benefit)USD | — | — | -204,000Source | 1,320,000Source | -106,000Source | 272,000Source | 253,000Source | 459,000Source | -4,456,000Source | 2,930,000Source | 1,561,000Source | 0Source |
| Net Income (Loss) Attributable to ParentUSD | — | — | 7,985,000Source | 11,550,000Source | -19,032,000Source | 668,000Source | -16,619,000Source | 13,158,000Source | 5,863,000Source | 27,588,000Source | -11,938,000Source | -87,400,000Source |
| Earnings Per Share, BasicUSD per share | — | — | 0.03Source | 0.04Source | -0.06Source | 0Source | -0.05Source | 0.04Source | 0.02Source | 0.1Source | -0.04Source | -0.34Source |
| Earnings Per Share, DilutedUSD per share | — | — | 0.03Source | 0.04Source | -0.06Source | 0Source | -0.05Source | 0.04Source | 0.02Source | 0.1Source | -0.04Source | -0.34Source |
| Weighted Average Number of Shares Outstanding, Basicshares | — | — | 306,806,000Source | 274,998,000Source | 309,191,000Source | 304,954,000Source | 308,267,000Source | 303,481,000Source | 305,639,000Source | 274,415,000Source | 267,014,000Source | 257,092,000Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | — | — | 311,638,000Source | 284,693,000Source | 309,191,000Source | 311,484,000Source | 308,267,000Source | 320,897,000Source | 314,112,000Source | 283,844,000Source | 267,014,000Source | 257,092,000Source |
| Interest Expense (non-operating)USD | — | — | 1,364,000Source | 1,801,000Source | 11,894,000Source | 285,000Source | 7,478,000Source | 4,645,000Source | 13,830,000Source | 11,981,000Source | — | — |
| Additional Financial Items | ||||||||||||
| Amortization of Intangible AssetsUSD | — | — | — | — | 4,367,000Source | — | 4,367,000Source | — | 3,973,000Source | — | — | — |
| Costs and ExpensesUSD | — | — | 63,234,000Source | 57,319,000Source | 109,724,000Source | 71,228,000Source | 91,838,000Source | 56,061,000Source | 310,165,000Source | 212,917,000Source | 190,284,000Source | 163,880,000Source |
| Current Income Tax Expense (Benefit)USD | — | — | — | — | — | — | — | — | 493,000Source | 2,915,000Source | 1,555,000Source | — |
| Depreciation, Depletion and Amortization, NonproductionUSD | — | — | — | — | — | — | 6,382,000Source | 2,106,000Source | 12,284,000Source | 7,371,000Source | 4,535,000Source | 6,124,000Source |
| Foreign Currency Transaction Gain (Loss), RealizedUSD | — | — | 120,000Source | -2,454,000Source | 486,000Source | -5,363,000Source | 1,318,000Source | -2,509,000Source | -7,749,000Source | 3,907,000Source | -1,916,000Source | 4,811,000Source |
| General and Administrative ExpenseUSD | — | — | — | 10,823,000Source | — | — | — | — | — | — | 42,538,000Source | 37,720,000Source |
| Goodwill, Impairment LossUSD | — | — | — | — | — | — | — | — | 0Source | — | — | 0Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | — | — | — | — | — | — | — | — | 1,407,000Source | 30,518,000Source | -10,377,000Source | -87,400,000Source |
| Interest ExpenseUSD | — | — | — | — | — | — | — | — | — | — | 15,151,000Source | 9,552,000Source |
| Interest Expense, DebtUSD | — | — | — | — | — | — | — | — | — | — | — | 15,011,000Source |
| Investment Income, InterestUSD | — | — | 2,628,000Source | 3,179,000Source | 1,022,000Source | 1,832,000Source | 1,429,000Source | 1,956,000Source | 8,053,000Source | 12,615,000Source | 6,154,000Source | 2,513,000Source |
| Nonoperating Income (Expense)USD | — | — | -11,115,000Source | 110,000Source | -18,788,000Source | -4,359,000Source | -14,699,000Source | -8,676,000Source | -37,394,000Source | -42,069,000Source | -19,055,000Source | -23,290,000Source |
| Operating ExpensesUSD | — | — | — | 18,023,000Source | 29,540,000Source | 20,568,000Source | — | — | 87,960,000Source | 76,602,000Source | 62,771,000Source | 57,497,000Source |
| Selling ExpenseUSD | — | — | — | 13,093,000Source | — | — | — | — | — | — | 51,776,000Source | 53,753,000Source |
| Other Income | — | — | — | —Source | — | — | — | — | — | — | — | — |
Filing attachments
tm2621100d4_ex99-1.htm · SCHEDULE 13G · 2026-08-14
EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The undersigned acknowledge that each shall be responsible for the timely filing of such amendments, and for the …
Read attachment ↗mnkd-ex99_1.htm · 8-K · 2026-08-05
EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update • Achieved three major catalysts to drive future growth: o Launched the pediatric indication of Afrezza® following FDA approval o FUROSCIX ReadyFlow™ autoinjector approved for treatment of edema in HF and CKD o Positive nintedanib DPI Phase 1b data in IPF patients validates continued Phase 2 advancement • Encouraging early momentum in Afrezza pediatric launch…
Read attachment ↗d63182dex41.htm · 8-K · 2026-07-24
EX-4.1 2 d63182dex41.htm EX-4.1 EX-4.1 Exhibit 4.1 THIS WARRANT AND THE SHARES OF COMMON STOCK ISSUABLE UPON THE EXERCISE OF THIS WARRANT (THE “SECURITIES”) HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE OF THE UNITED STATES. THE SECURITIES HAVE BEEN ACQUIRED FOR INVESTMENT AND MAY NOT BE SOLD, TRANSFERRED OR ASSIGNED UNLESS (I) SUCH SECURITIES HAVE BEEN REGISTERED FOR SALE PURSUANT TO THE SECURITIES ACT, (I…
Read attachment ↗d63182dex42.htm · 8-K · 2026-07-24
EX-4.2 3 d63182dex42.htm EX-4.2 EX-4.2 Exhibit 4.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of July 23, 2026, is entered into by and among MannKind Corporation, a Delaware corporation (the “Company”), and the several investors signatory hereto (individually, as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms used herein and not otherwise defined herein shall have the r…
Read attachment ↗d63182dex991.htm · 8-K · 2026-07-24
EX-99.1 4 d63182dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 MannKind Announces $50 Million Private Placement DANBURY, Conn. and WESTLAKE VILLAGE, Calif., July 24, 2026 (Globe Newswire) - MannKind Corporation (Nasdaq: MNKD), a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions for cardiometabolic and orphan lung diseases, today announced that it has entered into a securities purchase agreement in connection with a private plac…
Read attachment ↗mnkd-ex99_1.htm · 8-K · 2026-05-06
EX-99.1 2 mnkd-ex99_1.htm EX-99.1 EX-99.1 MannKind Reports First Quarter 2026 Financial Results and Provides Business Update Q1 updates: Q1 2026 total revenues of $90.2M, +15% vs. Q1 2025 Built out launch infrastructure and aligned field-based teams for upcoming launches Settlement of senior convertible notes of $36.3M Program updates: Afrezza® pediatric indication PDUFA date May 29, 2026 Furoscix ReadyFlow™ Autoinjector PDUFA date July 26, 2026 Nintedanib DP…
Read attachment ↗